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ABSTRACT
The field of nanotechnology research has seen a large growth in the past few
decades due to the great potential of novel nano-size material for useful applications such
as drug delivery and medical imaging. Also, they are a promising platform for the
detection of terrible diseases such as cancer and atherosclerosis. Although these
materials hold great promise, there is very limited understanding about the biological
effects of these nanoparticles on normal healthy cells, such as vascular smooth muscle
cells (VSMCs). The VSMCs are unique cells due to the two distinct phenotype
characteristics it can express: a contractile and a synthetic phenotype. Normally, they
express a contractile phenotype for their primary function of regulating the lumen
diameter of blood vessels. They also can express a synthetic phenotype when vascular
injury occurs.
In this study, the effects of different size citrate capped gold nanoparticles on the
mechanical properties of vascular smooth muscle cells subject to mechanical stretching
was investigated. The first part of the experiment assessed the cytotoxicity of the
nanoparticle treatment on the cell. Next, the assessment of the mechanical properties was
examined using atomic force microscopy (AFM) for cyto-indentation. The final part of
the investigation was immunofluorescence staining to look at the alpha actin within the
cell for possible phenotypic shift.
The study showed the citrate nanoparticles did not have any toxic effects on the
cells, but the nanoparticle treatment did alter the mechanical properties and phenotypic
expression of the VSMCs. Under static condition, the nanoparticle treatment decreased
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the mechanical properties of the cells. The size of the nanoparticle also had a decreasing
elastic modulus effect on the cell. The VSMCs subjected to mechanical stretching
exhibited higher elastic modulus compared to the static experimental groups. The
nanoparticle treatment also decreased the mechanical properties of the cells. However,
the size of the nanoparticle did not have any influence on the decrease of the cells elastic
modulus unlike the static treated cells. The mechanical testing condition provided a
better look at how these particles would affect the cells in vivo. While the nanoparticles
are not cytotoxic to the VSMCs, they are altering the mechanical properties and
phenotype of the cell.
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CHAPTER ONE
INTRODUCTION
1.1 Motivation:
Nanotechnology research, such as development of different nanoparticles for
therapy and imaging of different diseases have shown many promises, especially with
possible detection and treatment methods for cancer. Within the past decade, an
increasing number of research studies and publications using nanomaterials to treat and
detect cardiovascular disease, such as atherosclerosis, are emerging. As with any disease,
early detection will help aid the process of treatment and prevention of further
development of the disease, but there is still limited understanding of the total effects of
these nanoparticles on certain cells within our body.
The cardiovascular system is a significant area of research for many scientific,
medical, or engineering disciplines. The cardiovascular system includes the heart and
blood vessels that pump and transport different nutrients and waste from one part of the
body to another. If the cardiovascular system becomes damaged, the entire body is
affected. Cardiovascular disease is the leading cause of death in the United States.
Many people in the U.S. do not recognize or realize the symptoms and indicators of
cardiovascular disease; therefore, a lot of cases go undiagnosed until severe treatment is
needed. Many cardiovascular diseases affect blood vessels, the major transportation
pathway for blood through the body. In particular, atherosclerosis is a particular disease
that occurs when cholesterol and triglycerides accumulate on the walls of blood vessels.
Initially, the build-up has limited blood flow effects; however, once the disease
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progresses, the accumulation begins to seriously constrict the fluid flow, a cascade of
symptoms that can ultimately cause death occurs. Nano-technological research is
emerging to tackle the challenges of atherosclerosis and the effects it has on the body.
However, there is limited understanding about how these particles interact and affect
normal cells, such as vascular smooth muscle cells. This lack of information could be
dangerous if these nanoparticle interactions yield an adverse response. Therefore, an indepth investigation is required to figure out the interactions between healthy cells and
these nanoparticle with these nanoparticles, and how these interactions affect the overall
characteristics, mechanical properties, and/or functions of the cells.
The purpose of this research is to improve upon the understanding of how these
new nanomaterials, particularly gold nanoparticles, will affect the vascular smooth
muscle cells found in blood vessels.

1.2 Research Goal:
Investigate the influence of different size citrate capped gold nanoparticles on the
mechanical properties of vascular smooth muscle cells subjected to mechanical
stretching.
Aim 1: Evaluate the cytotoxicity of gold nanoparticles on VSMCs
Aim 2: Evaluate the effects of the size of the nanoparticles on the mechanical
properties VSMCs
Aim 3: Evaluate how the nanoparticles influence the phenotype expression by
assessment of the shape, size, and alpha-actin distribution and arrange of the cell.
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CHAPTER TWO
GOLD NANOPARTICLES IN BIOMEDICAL RESEARCH
2.1 Introduction:
In recent decades, the use of nanoparticles, particularly metallic nanoparticles, has
increased in biomedical research.[1] The small size allows for interaction with DNA,
proteins, lipids, and other cellular components. Common metallic nanoparticles studied
include gold, silver, titanium oxide, and iron oxide nanoparticles.[2], [3] Gold nanoparticles
(AuNPs) possess distinct chemical and physical properties and are one of the most widely
investigated materials. [3-4] Gold nanoparticles unique properties include: (a) capable of
synthesizing in a wide variety of sizes from 1 nm -100 nm, (b) controlled synthesis into
various shapes such as nanospheres, nanorods, nanocubes, nano shells, etc., (c) large
surface area to volume ratio, (d) stability over a wide range of temperatures, (e) easily
functionalized as seen in Figure 2.1 with different conjugates such as thiols, amines,
DNA, enzymes, antibodies, and some functional polymers.[2] All these properties can be
readily manipulated depending on the desired application. Thus, nanoparticles and the
field of nanomedicine provide a promising platform for various solutions for the
enhancement of different bioimaging modalities, drug delivery applications, cancer
diagnosis and treatment, and many other biomedical applications. [4], [6]–[8] However,
while nanotechnologies have shown great promise in these areas, long-term biological
effects of the nanoparticle and cellular interaction are not fully understood. Some studies
have shown adverse effects due to exposure of certain nanoparticles.[9], [10] Therefore,
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there is a need for the investigation of the effects of these gold nanoparticles on cellular
functions. Understanding the interaction between the cell and the gold nanoparticle is
important for safe and effective use of these nanomaterials. In this review, biomedical
research using nanoparticles, particularly gold nanoparticles, for drug delivery, imaging
enhancement, cancer research, and cytotoxic studies will be explored.

Figure 2.1: Multifunctional Gold Nanoparticle. The following are
illustrated: the ability to carry one or more therapeutic agents;
biomolecular targeting through one or more conjugates antibodies or
other recognition agents; imaging signal amplication, and biobarrier
avoidance by conjugated with polyethylene glycol (PEG) for avoidance
of macrophage uptake.[6]
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2.2 Gold Nanoparticles in Drug Delivery Applications
Targeted drug delivery system (TDDS) is among the most important research area
in biomedical engineering and pharmacology. The goal of TDDS is to increase the
concentration of the drug in the tissue of interest to enhance the therapeutic effects while
leaving the normal, healthy tissue unaffected. The reasons nanoparticles are being
researched for drug delivery applications are due to the small size, cellular interaction
compatibility, large surface to volume ratio, and ease of functionalization of the
particles.[2], [11], [12] These unique characteristics of nanoparticles allows large surface
coverage of a desired drug on particles, via ligands or other biomolecules, that because of
its size, will have the capability to bypass many bio-barriers in the body, target a
particular tissue of interest, and reduce overall systemic toxicity. The incorporation of
drugs onto the nanoparticle would help improve drug solubility; thereby, offering a more
regulated drug release with enhanced retention at the target site.[13] One research group
lead by Niidome has examined one of these challenges. To bypass the reticuloendothelial
system (RES), which consists of cells that filter out and destroy bacteria, viruses, and
other foreign substances, AuNPs were conjugated with thiol-derivative polyethylene
glycol (PEG-SH). The study found that this PEG-SH outer coating on the cetyl
trimethylammonium bromide (CTAB) capped AuNPs could delay RES clearance to the
liver from 30 minutes to 72 hours in mice models, an approximately 150-fold
improvement compared to unmodified CTAB capped AuNPs.[14] This controlled delay is
a significant advancement for drug delivery applications. The unique properties
nanoparticles offer enable scientists to research and solve more obstacles, such as how to
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treat diseases in the brain, which is a significant challenge for many drugs cross the
blood-brain barrier.[15]
Gold nanoparticle drug delivery has potential use as a feasible platform for the
targeting and treatment of many cancers. Kudgus et al. have shown the utilization of
Gemcitabine conjugated AuNPs inhibited the growth of Pancreatic Adenocarcinoma.[16]
Another study successfully delivered Doxorubicin, anti-cancer drug, into the nucleus of
melanoma cells in mice.[17] Many other drugs, such as Oxaliplatin, Paclitaxel, and
Cisplatin, conjugated with AuNPs are being researched for different treatments of cancer
such as melanoma and prostrate cancer.[1], [18]–[20]
Another drug delivery application with AuNPs includes loading them with
biomolecules. Joshi et al. investigated the utilization of oral and intranasal administration
of colloidal gold nanoparticles conjugated with insulin to diabetic rats in order to reduce
blood sugar levels. The studied reported a significant decrease in blood sugar which was
comparable with the decrease obtained by subcutaneous insulin injections.[21] Another
study investigated the potential of AuNPs for vaccine delivery for the hepatitis B virus.
These Chitosan-6-AuNPs have been studied for their efficiency concerning in vitro and in
vivo applications. When delivered intramuscularly to mice, these conjugated AuNPs
were more efficient than the naked DNA vaccine. The study also found these particles
induced cytotoxic T lymphocyte responses at a lower dosage when compared to bare
DNA.[22]
There exist numerous completed and on-going research studies on using
nanoparticles as a drug delivery vehicle for the treatment of many diseases, such as
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cancer. AuNPs offer many unique attributes allowing for novel drug delivery strategies to
be discovered. The key issue is the engineering of these particles for targeting the
specific site of interest, optimizing the bioavailability, and reducing any adverse
response.
2.3 Gold Nanoparticles in Imaging Enhancement Applications
There are many imaging modalities such as X-rays, Computed Tomography (CT),
Positron Emission Tomography (PET), and Magnetic Resonance Imaging (MRI) used
daily in clinical settings. These analytical machines help medical professionals view the
internal anatomy of a patient to look for abnormalities. Although these imaging methods
are beneficial tools, there are still complications and limitations with each of the
techniques. For example, iodine and bismuth are used as contrasting agents to address
contrast resolution problems; however, these contrasting agents have limited circulation
life due to fast filtration by the kidneys, toxicity of the agents at certain concentrations,
and the limited control for agent site targeting. In the past decade, research regarding
AuNP conjugates as a possible contrast agent for different imaging modalities has been
explored.
One of the most widely used and inexpensive imaging techniques is the X-ray.
X-rays provide rapid clear results of the interior of a patient’s body. Because of X-ray
low radiation doses, they do not provide the high soft tissue contrast that the CT and MRI
scans offer. In order to increase x-ray contrast, some studies have explored using AuNPs.
One study has effectively shown AuNPs were efficient enough to be used as an X-ray
contrast agent in vivo. Hainfeld et. al. injected 1.9 nm AuNPs into mice. The injected
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mice were x-rayed and blood vessels as fine as 100 µm in diameter could be
distinguished. The animal study demonstrated AuNPs are useful x-ray contrasting agents
that offer novel physical and pharmacokinetic advantages over current standard iodine
based agents.[23]
Gold nanoparticles were also explored for their applications in improving CT and
MRI imaging techniques. Kim et. al. performed an in vivo study using Sprague-Dawleys
rats. The 20-50 nm diameter PEG coated AuNPs intravenously administered to the rats.
The CT imaging results of the AuNPs treatment were compared to the current iodinebased contrast agent, Ultravist. The study found a greater efficiency in the contrast using
the AuNPs compared to the Ultravist contrast agent. The AuNPs also had a improved
circulation time and no renal toxicity; two limitations of using an iodine based contrast
agent.[24] Another studied used Gadolinium Chelate coated AuNPs as a possible contrast
agent for both CT and MRI scans. They also found that gold nanoparticles was a better
contrast agent than currently used agents and no undesirable effects were observed during
the administration of the nanoparticles or 6 weeks following the treatment.[25]
The use of AuNPs as a contrast agent in different imaging modalities is a feasible
possibility for future clinical settings. However, before AuNP implementation in clinical
settings, a lot more research has to be performed to study the effects the particles have on
the human body. Much of the current investigations focused on the feasibility of AuNPs
as a contrast agent and the possibility of using the particles as an imaging agent for the
detection of cancer.[5], [26]–[29] There are also recent studies emerging that involve the use
of nanoparticles for imaging cardiovascular diseases.[30], [31] These two focuses of AuNPs
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will be discussed in more detail in the following sections. Overall, AuNPs have
demonstrated their promising use in another biomedical research area.
2.4 Gold Nanoparticles in Cancer Research
Cancer is the third leading cause of death (after heart disease and stroke) in
developed countries and the second leading cause of death (after heart disease) in the
United States.[27] According to cancer statistics performed by the American Cancer
Society in 2010, near 600,000 deaths per year are a direct result from cancer and almost
1.5 million new cancer cases are diagnosed yearly in the U.S. alone.[32] The highest
survival chance for patients diagnosed with cancer relies on early detection and
prevention methods. The unique properties of AuNPs offer various advantages that are
currently being studied to assist with cancer detection, treatment, and prevention.
There are many different studies investigating the effects of AuNPs on different
types of cancer, see Table 2.1. These experiments all demonstrate the plausible
applications of AuNPs for cancer diagnosis and treatment. For instance, Wang et. al. used
acetylated dendrimer-entrapped gold nanoparticles (ADENPs-AuNPs) for the imaging of
human lung adencarinoma cell lines in vitro and in vivo. The results showed the ADENsAuNPs were able to assist in the detection of the prescence of cancer cells using CT
scans. The study also indicated no sign of cytotoxicity due to the AuNPs at the
concentration used in the study.[29]
Besides just detecting the presence of cancer cells, researchers are hoping to use
AuNPs as a therapeutic agent to treat cancer tumors. Researchers at the Mayo Clinic
looked at the effects of Gemcitabine conjugated AuNPs on the growth of pancreatic
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adenocarcinoma in vitro and in vivo. The study found that these particles were effective
in inhibiting the growth of the tumor in advance stage models. Further research is being
conducted to improve the efficacy of the nanosystem and gain greater understanding
about the pharmacokinetics.[16] However, not all the studies have shown promising
results. One studied looked at 5nm diameter Gadolinium conjugated AuNPs effects on
MC7 breast cancer cells. The in vitro study showed promising results with a cytotoxic
effect of up to 55% on the cancer cells. However, the in vivo studied showed no
significant difference between the treated and untreated mice.[19]
More work still needs to be completed before AuNPs could be a robust and highly
effective option for the treatment of cancer in the clinical setting. The field of
nanotechnology has made a significant amount of progress, but there are still many
unanswered questions regarding the use of AuNPs for the treatment of cancer. There is
huge potential for the use nanoparticles in cancer therapy, and with the intense global
interest in nanotechnology and nanomedicine; it is likely that many of these questions
will be addressed in the future.
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Table 2.1: This table list the research on using gold nanoparticles for the possible detection and treatment of
different type of cancers.[32]

2.5 Cytotoxicity of Gold Nanoparticles
Gold nanoparticles are intentionally engineered to interact with cells; therefore, it
is important to ensure that these modifications do not cause any adverse effects in the
body. For biomedical purposes, especially in vivo applications, toxicity is a main factor
to investigate when evaluating the potential and effectiveness of the nanomaterial.
Cytotoxicity is one of the most common criteria used to assess the effects of the
nanoparticles on cells and the particles viability for use within the body. However,
studies analyzing toxicities of AuNPs have a significant amount of uncertainty and are
difficult to compare quantitatively. The difficulty occurs because of variability in the
type of nanoparticles, different size particles, different cell lines, concentration, exposure
time, incubation time, and cytotoxicity assays used for the analyses.[3] Despite these
variables, there are trends that can be extracted and compared qualitatively from the
many studies.
One of the parameters many investigations have examined is the effect of size on
the toxicity of the cell. A particular study performed by Coradeghini et.al. investigated
mouse fibroblasts (3T3s) exposed to citrate stabilized AuNPs.[33] The authors presented
evidence that 5nm diameter citrate capped AuNPs were cytotoxic to the 3T3s at
concentrations greater than 50 µM. Meanwhile, 3T3s exposed to 50, 100, 200, and 300
µM of 15nm diameter citrate stabilized AuNPs had no indication of toxicity.[33] Another
study performed by Pernodet et. al. reported that 14nm diameter citrate capped AuNPs
decreased cell proliferation and possessed slight signs of toxicity in human dermal
fibroblasts.[9] The toxic effects observed in the study were attributed to actin stress.
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However, a second, independent study performed by Li et.al. also reported the same
effects in the presence of citrate-capped AuNPs with human lung fibroblasts, but the
presented evidence actually indicated that cytotoxicity was a result of oxidative
damage.[34] Connor et al researched utilizing human leukemia cells (K562) with particle
sizes ranging from 4 to 18 nm in diameter and surface modifiers of citrate, biotin, and
cysteine, and glucose. These cells showed no signs of toxicity at concentrations up to
250 µM.[3],[35]
Another study by Liu et. al. compared the effect of surface charge of AuNPs and
the correlation it had with the cytotoxicity level. The results revealed that when using a
MTT Cytotoxicity assay on HepG2 cells, positively charged 10-(mercaptodecyl)trimethyl-ammunium bromide (AuNP-TMA) exhibited higher cytotoxicity than the
negatively charged 11-mercaptoundecaonic acid (AuNP-MUA). Conversely, it was
determined that negatively charged AuNP-MUA showed a higher cytotoxicity level than
the positively charged AuNP-TMA in RAW 264.7 cells when using the same MTT assay.
Utilizing a LDH assay indicated that a positively charged AuNP-TMA had a higher
toxicity effect than the negatively charged AuNP-MUA in not only the HepG2 cells, but
also the RAW 264.7 cells.[36] The authors found in this study that toxicity did not show
significant physiochemical property, such as size and surface functionality, dependence.
Rather, this study indicated that cytotoxicity was more reliant on cell interactions with
AuNPs between the two different cell lines and the type of colorimetric assay used to
assess the cell viability.[36]
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There exist many other cytotoxic studies examining the effects of size, shape,
surface chemistry, uptake, concentration, colorimetric assayss, cell types, and culturing
conditions.[3], [37]–[41] Based on these current findings, the amount of cytotoxicity derived
from the AuNPs versus other experimental variables and methods is unclear. Thus,
conflicting data exist with regard to the toxicity of AuNPs that requires further
examination to fully understand the possible adverse effects from AuNPs.
2.6 Conclusion
In summary, AuNPs have emerged as a promising alternative or additive for
many different biomedical applications, such as drug delivery, medical imaging, and
cancer diagnosis and treatment. Nanotechnology could also be a useful tool for other
diseases such as Tuberculosis and Alzheimer’s. Further research to fully understand
AuNPs and their effects within the human body, must be performed before clinical trials
can occur. Nevertheless, nanotechnology and its potential applications are expected to
provide significant advancements in medicine.
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CHAPTER THREE
THE SIGNIFICANCE OF VASCULAR SMOOTH MUSCLE CELLS

Figure 3.1: The anatomical breakdown of the different layers of arteries,
veins, and capillaries. Blood vessels are made up of three different layers:
tunica intima, tunica media, and tunica externa. Vascular smooth muscle
cells (VSMCs) make up most of the tunica media in arteries and veins.[42]
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3.1 Background of Vascular Smooth Muscle Cells
The human body contains a vast network of blood vessels that delivers nutrients
and oxygen throughout the body. The vessels can be categorized into three different
types of structures: arteries, veins, and capillaries.[42] Arteries and veins are constructed
out of layers.[42] The innermost layer is the tunica intima, which is the main layer that is
normally in contact with the blood.[42] The tunica intima is composed of simple
squamous epithelial cells (endothelium lining) and a sub-endothelial layer of connective
tissue. The endothelium lining creates a smooth surface blood to flow without damage.[43]
The middle layer of the blood vessel is called the tunica media. The tunica media is
comprised mostly of circularly arranged vascular smooth muscle cells (VSMCs), but
other material such as collagen (type I, III, and V), elastin, and proteoglycans are also
found in this layer. The tunica media’s main function is to contract and relax the blood
vessel walls to maintain steady blood flow. The outermost layer is the tunica externa or
adventitia. This layer is comprised mostly of loose connective tissue made up of type I
collagen fibers and some elastin fibers. This outer layer assists in anchoring the vessels
within the body and counteracts external forces, such as longitudinal stretching.[44] All
three layers shown in Figure 3.1 make up the arteries and veins in the cardiovascular
system throughout the human body.
Vascular smooth muscle cells are specialized cells designated to regulating the
lumen diameter in blood vessels. This diameter control dictates contraction and dilation
of the vessel walls and determines the blood distribution and pressure throughout the
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body. Another special characteristics of VSMCs are that they are able to change their
phenotype contractile or synthetic phenotype, between contractile or synthetic, in
response to environmental factors. (see Figure 3.2)
Normally, VSMCs in the tunica media express the contractile phenotype. A
significantly low rate of proliferation is exhibited and the cells express specific and
unique contractile proteins.[45] The other phenotype VSMCs can undergo change into is
the synthetic or proliferative phenotype. The synthetic phenotype expression is
characterized by high proliferation rate, migration, and extra cellular matrix secretion,
especially collagen type III and fibronectin. This phenotype is typically expressed by the
VSMCs in response to vascular injury and plays a vital role in vascular repair. However,
the downside to this phenotypic modulation or switching prompts the cells to respond to
environmental signals readily leading to development of vascular diseases such as
atherosclerosis, hypertension, and neointima formation. [34]
3.2 Research Interest in Vascular Smooth Muscle Cells
The ability of VSMCs to change their phenotype based on environmental stimulus
plays a critical role in vascular repair. Unfortunately, the altering phenotype
characteristic is also a main factor in the development and progression of atherosclerosis.
Researchers are beginning to better comprehend some of the molecular mechanisms and
factors that controls transitions in the phenotypic state of the VSMCs, but little is known
about what controls the etiology and advancement of the different stages of
atherosclerosis. Atherosclerosis is considered a chronic and complex disease that can
ultimately result in the occlusion of the affected arteries and cause life-threatening
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damage such as myocardial infarction or stroke. This disease usually begins with some
sort of endothelial dysfunction or damage, which allows for increase accumulation of
plasma-derived lipids and their oxidation products into the matrix of the arterial wall.
The intimal cells react by recruiting inflammatory cells to the site of injury, initiating the
migration of monocytes into the vessel wall. The monocytes become macrophages and
ingest the oxidized lipid; thus, forming what many research call “foam cells”. The
recruitment of macrophages, and the production of inflammatory cytokines, oxygen free
radicals, and other cascade factors lead to a downstream effect. This chain of reactions
induces the migration of the VSMCs from the medial layer into the intima layer. The
VSMCs begin to proliferate and synthesize matrix molecule to remodel the vascular wall
a process also known as neointimal hyperplasia. This process continues until the lumen
of the blood vessels becomes increasingly occluded and eventually leads to a blockage of
blood flow.[46], [47] A schematic of the process of the development of atherosclerosis can
be seen in Figure 3.3.
Current treatment for atherosclerosis includes using grafts to bypass the area of
blockage, or implanting a vascular stent to open up the occluded vessel. However, these
solutions possess unique complications and side effects. There exist many current
biomedical research projects focusing on the development of tissue-engineering blood
vessels to try to combat this disease. Emerging nanotechnology research aims to use
nanomaterials to detect early signs and possibly even treat atherosclerosis.
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Figure 3.2: Phenotypic modulation or switching of vascular smooth muscle cells. The
left side illustrates and list characteristic the characteristic of synthetic or proliferative
phenotype. The main feature to focus on is the lack contractile fibers, increase
organelles for the production and secretion of extracellular matrix. The right side
illustrates and list characteristic the characteristic of contractile phenotype. The main
feature to notice is the abundance of contractile fibers spanning the cell body. [46]

3.3 Conclusion:
Vascular smooth muscle cells are important because they help blood vessels in the
body to distribute and maintain a steady blood flow, that provides nutrients throughout
the body. VSMCs have the ability to change phenotype in response to different
environmental stimuli such as mechanical or chemical factors to assist in maintaining a
stable environment. These cells also are significant in the development and progression
of atherosclerosis. Research with regards to VSMCs will further the understanding about
the type of factors or even new materials such as nanoparticles, that will affect there
phenotypic change and the ramifications these alterations will ultimately have on the
body.
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Figure 3.3: Development of Atherosclerosis. The disease begins with of
damage to the endothelium lining or endothelial dysfunction. The image shows
different stage of the disease and what each stage looks like. An important
factor to notice is throughout the entire development and progression of
atherosclerosis the disease is deemed clinically silent up until the advance
stages.[42]
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CHAPTER FOUR
THE EFFECTS OF DIFFERENT SIZE GOLD NANOPARTICLES ON THE
MECHNICAL PROPERTIES OF VASCULAR SMOOTH MUSCLE CELLS
UNDER PHYSIOLOGICAL STRESS
4.1 Abstract:
Nanotechnology is an emerging and promising frontier for medicine and
biomedical research due to its potential for applications such as drug delivery, imaging
enhancement, and cancer treatment. While these materials may possess significant
possibilities, the effects of these particles in the body and how the particles affect the
cells is not fully understood. In this study, vascular smooth muscle cells (VSMCs) will
be exposed to 5 and 20 nm diameter citrate AuNPs under mechanical conditions. The
cytotoxicity properties of these particles will be investigated using LDH and MTT assays.
Atomic force microscopy will be used to study how the size of the nanoparticles affect
the mechanical properties of the VSMCs. Immunofluorescence staining for alpha actin
will also be performed to enhance understanding of the phenotypic shift. The LDH and
MTT cytotoxicity assay results demonstrated that neither 5 nor 20 nm diameter
nanoparticles are cytotoxic to the cells. However, the mechanical properties and cell
morphology of the VSMCs was altered. Under static conditions, both AuNP treatments
decreased the mechanical properties of the cells. The size of the nanoparticles had a
softening effect on elastic modulus of the cell and sign of a synthetic phenotype was
observed. The VSMCs subjected to mechanical stretching exhibited higher elastic
modulus compared to the static experimental groups. Again, both AuNPs treatments
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decreased the mechanical properties of the cells and signs of more synthetic phenotype
was seen. However, the size of the nanoparticles did not have any influence on cell’s
elastic modulus unlike the static treated cells. The mechanical testing condition provided
a better look at how these particles would affect the cells in vivo. While the nanoparticles
are not cytotoxic to the VSMCs, they are altering the mechanical properties and
phenotype of the cell.

22

4.2 Introduction:
In recent decades, the use of nanoparticles, particularly the use of AuNPs has
increased in biomedical research. Their small size and unique properties allow these
particles to interact with cellular components. Gold nanoparticle unique properties
include: (a) wide variety of controllable sizes from 1 nm -100 nm, (b) Controlled shape
variety, such as nanospheres and nanorods (c) large surface area to volume ratio, (d)
functionalized readily with different conjugates.[2] All these properties can be engineered
and altered depending on the particles intended application. Thus, AuNPs provide a
potential platform for development and application for the future of modern
medicine.[4],

[6]–[8]

However, while nanotechnology has shown great promises, some

biological effects of the nanoparticle and cellular interaction are not well understood.
Some studies have shown adverse effects on the body as results of nanoparticles
exposure. Understanding the interaction between the cell and the AuNPs will further the
overall understanding of how to use these nanoparticles properly and how they can be
applied in different biomedical applications, such as medical imaging, drug delivery, or
tissue engineering. Therefore, there is a need for the further investigation of the effects
of these AuNPs on cellular functions.
Vascular smooth muscle cells (VSMCs) play an important role in contracting and
relaxing the blood vessel walls to control blood flow and pressure. They also play a
critical role in vascular repair because of their unique capability to change phenotype
when vascular injury or other environmental factors occurs.[46]–[48] As the field of
nanotechnology moves into studying cardiovascular diseases[31], the understanding for
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how these nanoparticles affects cells in the cardiovascular system is substantially more
important.
One of the most important effects to investigate is the cell toxicity level when
exposed to these nanoparticles. Many nanoparticle studies have investigated the potential
cytotoxic effects of nanoparticles on various cell types.[3], [41], [49] However, there is not a
large understanding of the toxic effects these particles have on VSMCs. Common
toxicity assays used include the Lactate Dehydrogenase (LDH) assay and MTT assay.
The LDH assay is a colorimetric assay that measure cytotoxic level by measuring the
plasma membrane integrity. Lactate Dehydrogenase, which is a soluble cytosolic
enzyme present in the cell, releases upon cell death due to damage to the plasma
membrane damage. The MTT assay measures cytotoxic levels by quantifying the cell
metabolic activity based on the ability of mitochondrial succinate/tetrazolium reductase
system to convert the yellow dye (MTT) to purple formazan.
Another interesting factor that will be examined in this study is how a dynamic in
vitro testing condition will effect the mechanical properties of the cells, particularly
VSMCs, compared to just a static experimental conditions. Overall, there exist few
studies that actually evaluate how these nanoparticles influence the cells under
mechanical conditions. The human body is not a static object. The human body contains
chemical stimulation and mechanical stimulation. Investigating how these nanoparticle
affects the VSMCs under mechanical conditions in vitro will help improve upon the
understanding of the potential effects of these nanoparticle in vivo.
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This study will evaluate how 5 nm and 20 nm diameter citrate capped AuNPs
affect the mechanical properties of VSMCs under static and dynamic conditions, the
cytotoxic effects on the cell, and phenotypic shift due to exposure to the nanoparticles.
4.2 Material & Methods:
Cell Culturing:
Aortic VSMCs were isolated from adult Sprague Dawley rats. The VSMCs were
cultured in High Glucose Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco) with
10 % fetal bovine serum (FBS) (Sigma) and 1% antibiotic-antimycotic solution (Sigma).
VSMCs were incubated in polystyrene T-75 flasks at 37°C and 5% CO2. The cell culture
media was replaced every 48 hours. They were grown to approximately 70-80%
confluence in flasks. Between passages, the cells were trypsinized with 0.25% trypsin
with 0.02% ethyldiaminetetaacetic acid (Sigma). Cells between passage 3 and 8 were
used for experiments.
Nanoparticles Synthesis:
The 5 nm diameter citrate capped spherical AuNPs were prepared by using100 µL
of a 0.1 M citrate solution and 100 µL of 0.05 M of tetrachloroaurate (III) (HAuCl4). The
solution was next diluted in 20 mL of deionized water. The aqueous gold/citrate mixture
was then reduced by the addition of 100 µL of 0.05 M of sodium borohydride (NaBH4).
This synthesis yielded a ruby red AuNP dispersion.
The 20 nm diameter citrate capped spherical AuNPs were prepared by adding
500 µL of 0.05 HAuCl4 to 50 mL of deionized water. The solution was then heated.
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Next, 1 mL of 0.1 M citrate solution was added. This solution was stirred and heated for
at least 10 minutes. This synthesis method yielded a ruby red AuNP dispersion
Transmission Electron Microscopy (TEM) was performed to confirm the relative
size of the nanoparticles.
Flex Cell System:
The VSMCs were seeded into 6-well collagen plates (BioFlex) with 25,000 cells
per well. The cells were allowed to incubate over night to adhere to the plate. For the
static conditions and dynamic, 3 groups were made: control cells (CC), 5nm citrate
capped gold nanoparticle (5AuNPs), and 20nm citrate capped gold nanoparticles group
(20AuNP). These groups were also made for the dynamic conditions. Once the cells
were ready, 25 µM of phosphate buffered saline solution (PBS), Citrate solution, 5nm
AuNPs, 20 nm AuNPs were added to the CC, CCS, 5 nm AuNP, and 20 nm AuNP group,
respectively. To provide the dynamic condition, the Flex Cell 3000 System was used.
The plates were loaded onto the platform and place inside the incubator. The plates were
pre-conditioned under 0-4 % cyclic strain at 0.1Hz for 30 minutes and 0-4% cyclic strain
at 0.5 Hz for 30 minutes. Finally, the groups were allowed to run for 72 hours under 04% cyclic strain at 1.0 Hz.
Cytotoxicity Assays: LDH
The LDH assay kit used was CytoTox96® Non-Radioactive Cytotoxicity Assay
(REF#: G1781 & G1782) purchased from Promega Corporation. The VSMCs were
seeded into a 96-well plate at 10,000 cells per well. The cells were allowed to incubate
over night to adhere to the cell plate. The AuNPs were added at so that there were 5 µM,
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25 µM, and 50 µM concentration in the experimental wells. Each sample group
contained 6 wells. After treatment period of 3 days, the lysis solution was added at a
ratio of 15 µL per 100 µL of media. Incubated the well with the lysis solution for 60
minutes at 37°C and 5% CO2. Next, 50 µL of the supernatant of each of the wells were
transferred to a new 96 well plate. Then 50 µL of the reconstituted Substrate Mix was
added to each well. The plate was covered and incubated at room temperature for 30
minutes. Finally, 50 µL of the Stop Solution was added to each well and the absorbance
reading was taken at 490 nm.
Cytotoxicity Assays: MTT
The MTT assay kit used was CytoTox96® Non-Radioactive Cell Proliferation
Assay (REF#: G4001 & G4002) purchased from Promega Corporation. The VSMCs
were seeded into a 96-well plate at 10,000 cells per well. The cells were allowed to
incubate over night to adhere to the cell plate. The AuNPs concentration were added at
5 µM, 25 µM, and 50 µM to the experimental wells. Each sample group contained 6
wells. After a treatment period of 3 days,,15 µL of Dye Solution was added to each well.
The plate was allow to incubate for 4 hours at 37°C and 5% CO2. After the incubation
period, the media/dye solution was removed and 100 µL of the Solubilization/Stop
Solution was added to each well and the absorbance reading was taken at 570 nm.
Immunofluorescence Staining:
Immunofluorescence staining was performed to look at the smooth muscle alphaactin to see if there might be a phenotype change has occurred in the VSMCs based on
the alpha acting concentration and distribution. First, the cells were fixed in 4%
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Paraformaldehyde for 10 minutes and then washed 3 times with PBS. Next, the cells
were then permeabilized with a solution of PBS/0.01M Glycine/0.2% Triton-X (Sigma)
for 30 minutes. Then, the cells were incubated in blocking solutions with 10% Goat
Serum/PBS for 15 minutes. The cells were incubated with a dilution of 1:500 solution of
Monoclonal Anti-Actin, Alpha-Smooth Muscle Antibody produced in Mice (Sigma
Aldrich) with the blocking solution overnight at 4°C. After the cells were incubated over
night, the cells were washed with PBS 3 times. Next, the cells were soaked in a dilution
of 1:500 solution of Goat Anti-Mouse IgG(H+L) Fluorescein Conjugated Secondary
Antibody (Millipore) with PBS for 2 hours protected from light. After washing again
with PBS 3 times, the cells were next stained with a SlowFade Gold anti-fade reagent
with DAPI (Invitrogen). The fluorescence images were taken using EVOS®FL Cell
Imaging System (Life Technologies).
Atomic Force Microscopy (AFM):
Atomic Force Microscopy cytoindentation was performed on each sample 1- 24
hours after the 72 hours of static and dynamic (Flexcell stretching) conditions. The
collagen membrane was carefully removed prior to testing and placed into a small AFM
fluoro dish with 3 mL of new warm (37°C) media added into the dish. For the AFM
testing, the Asylum Research MFP-3D was operated in contact mode with a fluid cell. A
5 um diameter borosilicate spherical-tipped AFM probed with a spring constant of
0.2 N/m was used to mechanically indent into each individual cells. The AFM optical
microscope (40x) was used to position the tip of the cantilever over the cell center of the
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cell. For each sample, every cell was indented 5 times to approximately 1 um depth to
yield 5 force curves.
Force Curve Analysis of Data:
The force curves were exported from the AFM software and a series of MATLAB
scripts was utilized to analyze the data. All MATLAB scripts used for the analyze in this
experiment can be found in Appendix B. Next, a contact point was established from the
dataset at a displacement value where there is a rapid increase in the deflection. This
quick increase indicated contact between the cell and the tip. The offset for the deflection
was adjusted in the MATLAB code. After the adjustment, MATLAB measures the cell
stiffness/the apparent elastic modulus of the cell was calculated by fitting the data to the
Hertz Model. The model was fitted to the first 100-200 nm of data. The Hertz Model
used for a spherical indenter is defined in Figure 4.1.

Figure 4.1 (Above): Hertz Model used for a spherical indenter. F and d
represents the measured force and indentation depth respectively. The R
represents the radius of the tip, which was set to 2.5 um. The v
represents the Poisson’s Ratio, which was set to 0.5. The variable E is
the elastic modulus and the variable of interest in this equation.
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Statistical Analysis:
A Student’s t-test was performed on the data to compare the control conditions to
the experimental conditions to determine if any statistically significant differences existed
between the samples. A P-value of less than 0.05 was considered statistically significant.
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4.3 Results:
TEM of the Citrate Capped Gold Nanoparticles:

Figure 4.2: TEM image of the 5nm diameter (Left) and 20 nm diameter (Right) citrate
capped AuNPs.

TEM was performed to confirm the relative size of the nanoparticle. The image
on the left in Figure 4.2 shows the 5 nm citrate capped AuNPs. The sizes of these
particles are relatively around 5nm. The image on the right in Figure 4.2 shows the
20 nm citrate capped AuNPs. The sizes of these particles are relatively around 20 nm.
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Cytotoxicity Assays: LDH

Figure 4.3: The results for the LDH Cytotoxicity on VSMCs treated
with different concentrations of 5nm and 20nm citrate capped AuNPs.
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The LDH Cytotoxicity results showed that VSMCs treated with 5 µM, 25 µM,
and 50 µM of the 5nm AuNPs had a viability percentage of 98.68% ±2.72, 109.69%
±2.43, and 115.84% ±1.82, respectively. The 5 µM, 25 µM, and 50 µM of the 5nm
AuNPs showed viability percentage of 116.60% ±5.61, 109.92% ±2.13, and 117.36%
±2.14. There were no adverse signs of cytotoxicity on the VSMCs under all the tested
conditions. Some of the groups showed a higher viability percentage than the control.
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Cytotoxicity Assays: MTT

Figure 4.4: The results for the MTT Cytotoxicity on VSMCs treated
with different concentrations of 5nm and 20nm citrate capped AuNPs.
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The MTT Cytotoxicity results showed similar trends to the LDH Cytotoxicity
results. Again, no apparent cytotoxic effects were observed. The VSMCs treated with 5
µM, 25 µM, and 50 µM of the 5nm AuNPs had a viability percentage of 97.16% ±15.77,
104.35% ±12.02, and 100.98% ±12.02, respectively. The 5 µM, 25 µM, and 50 µM of
the 5nm AuNPs showed viability percentage of 98.67% ±11.13, 100.21% ±14.47, and
99.75% ±10.65. There were no adverse signs of cytotoxicity on the VSMCs under all the
tested conditions.
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Immunofluorescence Staining:
Static Condition

Dynamic Condition
B

C

D

E

F

20nm AuNPs

5nm AuNPs

Control

A

Table 4.1: The alpha-actin fluorescence images of the VSMCs with static and
dynamic experimental conditions exposed to 5 nm & 20 nm citrate capped AuNP.
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The VSMCs was stained to examine the alpha actin content to determine if a
phenotypic shift occurred. By looking at the actin distribution and arrangement using
immunofluorescence staining, these phenotypic changes can be visually observed. The
VSMCs stained under the static conditions can be seen in Figure 5.1.A, 5.1.C, and 5.1.E.
These VSMCs appear larger and shorter than the mechanical stretching/dynamic testing
VSMCs, which indicates the synthetic phenotype expression. The cells under the
mechanical stretching shown in Figure 5.1.B, 5.1.D, and 5.1.F appear more elongated
and thinner, a significant indication of a contractile phenotype expression. Besides the
shape and size of the VSMCs, the actin distributions of static and dynamic groups are
also different. The group subjected to mechanical stretching has a very neat and parallel
arrangement of the actin fibers within the cell, and this ordered arrangement supports
contractile phenotype characteristics. The static condition cells do not show an ordered
actin fiber orientation. The actin fibers appear to be randomly arranged, indicating that
these cells might be expressing more synthetic phenotype characteristics.
Elastic Modulus from AFM Analysis:
The effects of the citrate capped AuNPs on the mechanical properties of the
VSMCs can be seen from the elastic moduli results. The control cells cultured under
static conditions had an elastic modulus of 7.63±1.61 kPa. When the VSMCs were
treated with the 5 nm and 20 nm diameter citrate capped AuNPs, the elastic moduli of
those cells were 5.72±1.46 kPa and 4.53±1.56 kPa, respectively. Statistical analysis of
the elastic moduli of the static experimental group showed a statistical significance
(p<0.05) indicating there is a big change between the control and the experimental group.
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There was a significant statistical difference between the control cells and the
cells treated with both the 5 nm and 20 nm AuNPs. The results showed that the
nanoparticles had a softening effect on the mechanical properties of the cell. There was
also a significant statistical difference between the VSMCs treated with the 5 nm versus
the 20 nm AuNPs. This conclusion indicated that the increase in the size of the
nanoparticles decreased the overall mechanical properties of the treated cells, at least for
the static conditions. The cells treated with the two different size AuNPs showed
different effects.
The controls cells subjected to mechanical stretching had an average elastic
modulus around 11±1.10 kPa. The cells analyzed under mechanical stretching conditions
were treated with 5 nm and 20 nm citrate capped AuNPs had elastic moduli of
8.26±1.15 kPa and 8.53±1.93 kPa, respectively. Statistical analysis showed there was
only a significant statistical difference between the control cells and both nanoparticle
treated group, but no significant difference between the 5 nm treated cells and the 20 nm
treated cells. These results indicated that the nanoparticles caused a decrease in the
mechanical properties of the VSMCs regardless of static or dynamic testing conditions,
but the effect of particle size on the mechanical properties of the cells was only seen
under static testing conditions. The elastic moduli of all the cells subjected to mechanical
stretching were all significantly higher compared to the cells under the static
experimental conditions.
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Figure 4.5: The elastic modulus of the VSMCs under static condition. The data
showed there is a significant difference between the control and the nanoparticle
treated cells as well as directly between 5nm AuNP treated and the 20nm AuNP
treated cells.
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Figure 4.6: The elastic modulus of the VSMCs subjected to mechanical stretching
condition. The data showed there is a significant difference between the control
and the nanoparticle treated cells. There is not a statistical difference the two
nanoparticle treated groups.
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Figure 4.7: Comparison of the elastic modulus from the static experimental
groups to the dynamic experiment groups. The data showed that there is a
significant difference between the dynamic cell groups and the static cell groups.
The cells subjected to mechanical stretching had a higher elastic modulus.
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4.4 Discussion:
Based on the experimental results in this study, the 5 nm and 20 nm diameter
citrate capped AuNPs do not appear to have any cytotoxic effects on the VSMCs. Both
the LDH and MTT cytotoxic results in this study are similar to other literature findings.
However, even though the particles are not cytotoxic to the cells, they show some
influence on the mechanical properties of the VSMCs. Significant changes in the elastic
moduli seen from the AFM results as well as the shift in morphology and alpha actin
arrangement observed in the immunofluorescence staining, indicate that the AuNPs are
decreasing mechanical properties and altering some of the characteristics of the VSMCs.
This is a good indication of a phenotypic shift from a more contractile to a more synthetic
expression.
The elastic moduli of the static versus dynamic groups showed that the VSMCs
are more influenced by the nanoparticles under static conditions compared to dynamic
stretching conditions. The difference between the control cells under static condition and
the AuNPs treated groups indicated that the nanoparticles decreased the mechanical
properties of the cells. The differences between the average elastic moduli of the 5 nm
AuNP treated cells and the 20 nm AuNPs treated cells, suggested that the VSMCs
exposed to larger particles have a slightly lower modulus of elasticity. The actin
distribution and arrangement between the control and the static experimental groups also
indicated a more synthetic phenotype due to the rounder cells and lack of orientation of
the alpha-actin fibers. See Figures 5.1.C and Figure 5.1.E.
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The cells subjected to mechanical stretching yielded similar results with a few key
differences. The elastic moduli of the dynamic control VSMCs group was significantly
higher compared to both the AuNPs groups, but the change in the moduli based on
nanoparticle size was not observed. However, the effect on shape and size of the cells are
still seen. The VSMCs treated with AuNPs are apparently larger and rounder compared
to the control group, which has more elongated cells. The actin distribution and
arrangement appeared similar between all the dynamic experimental groups. The actin
fiber seems to orient in a distinct direction. This could be due to the presence of
mechanical stimulation that can cause the ordering of the actin stress fiber in a certain
direction.
Regarding the presence of mechanical stimulation, the AuNPs seems to be
influencing the mechanical properties and overall morphology of the VSMCs. This
observation could indicate a potentially adverse effect if these nanoparticles change the
VSMCs enough to alter the main cell function. Another complication also arises because
VSMCs play a critical role in the development and progression of atherosclerosis, and
any alteration to the VSMCs could exacerbate or decrease atherosclerosis development.
More testing needs to be performed to better understand the extent that the nanoparticles
are affecting the cell morphology, mechanical properties, and overall function, and the
ramifications these alterations have for cardiovascular diseases. Knowing that the AuNPs
are affecting the VSMCs furthers the understanding of the interactions between the
nanoparticles and cells but also presents other challenges for scientists and researchers to
address further.
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4.5 Conclusion:
Vascular smooth muscle cells exposed to citrate capped AuNPs cause changes in
the cell morphology and decreased the mechanical properties of the cells, with or without
mechanical stimulation. The size of the AuNPs only influences the mechanical
properties of VSMCs when the cells are under static conditions. The nanoparticles are
altering the alpha-actin formation within the cells. Future research needs to investigate
the intercellular processes and activities to further understand how the nanoparticles are
ultimately influencing the morphological changes and mechanical properties.
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CHAPTER FIVE
RECOMMENDATION FOR FUTURE WORKS
The results in this study provide further insight into the world of nanoparticles
and how they affect and interact with VSMCs. This project could be improved upon by
performing polymerase chain reaction (PCR) or Western Blotting targeting specific
markers to gather more evidence of phenotypic change due to the exposure of particles.
This study could also be repeated with a larger range of particle sizes, such as 2 nm,
15 nm, 30 nm, and 50 nm, to further confirm and understand the effect of particle size on
the VSMCs.
One of the main questions instigated by this study was where are these
nanoparticles depositing once they are inside the cell? Some literary papers have
reported that the nanoparticles are trapped in vesicles within the cells and others
suggested the nanoparticle are able to interact freely with substances in the cytoplasm.
Transmission electron microscopy or dual-photon microscopy techniques could be
performed to analyze the ultimate location of nanoparticles within the cells.
Understanding the nanoparticles location within the cell could provide a better
comprehension and prediction of possible effects these particles could be having on the
cell.
Another direction to take this research is to investigate how the exposure of these
nanoparticles affects a co-culture of vascular endothelial cells (VECs) and vascular
smooth muscle cells (VSMCs) cultured together. The novelty of this research is that the
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investigation will utilize two cell lines compared to just one cell type, and this will
simulate a more in vivo like environment. The study would look at the not only the
nanoparticles and the VSMCs interaction, but also the interaction between the
nanoparticles and the VECs as well as the VECs and the VSMCs. The results would
provide a greater insight into the nanoparticles effects on the blood vessels in vivo using
an in vitro model.
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APPENDICES

47

Appendix A
Isolating Vascular Smooth Muscle Cells

•

Sacrifice rat using CO2 asphyxiation and cervical dislocation

•

Remove aorta from subclavian origin to the diaphragm bifurcation and place in
DMEM with pen/strep

•

Use tissue culture hood to remove all adventitia and connective tissue. All adventitia
must be removed to ensure you only attain VSMCs

•

Cut vessel longitudinally so it lays flat and scrape off endothelium gently with scalpel
blade and rinse thoroughly in DMEM with pen/strep

•

Cut the vessel into ~5 mm squares and place them in digestion solution that includes
5 ml DMEM, pen/strep (1%), Collagenase type II (final concentration 175U/ml), and
10% FBS for 20 minutes

•

Centrifuge at 500 rpm for 1 minute and remove the supernatant and wash the pellet
with DMEM containing pen/strep

•

Resuspend the pieces in another digestion solution containing DMEM, pen/strep (1%)
Collagenase type II (final concentration 175U/ml), Elastase type III (final
concentration 0.25 mg/ml) and 10% FBS for 1 hour. Be sure to shake the tube gently
every 10 minutes until the vessel is gossamer thin. When the vessels are dissolved
stop the digestion by diluting with equal volume of DMEM with pen/strep and 20%
FBS

•

Centrifuge 1000 rpm for 5 minutes and remove the supernatant
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•

Suspend cells in DMEM with pen/strep and 20% FBS and place in T-25 flask and put
in incubator (37C, 5% CO2). Don’t change media for 72 hours as cells need
sufficient time to adhere to flask.

•

Maintain the cells using DMEM with 20% FBS and pen/strep until cells reach P4
then use 10% FBS

49

Appendix B
MATLAB Script for AFM Analysis
Hertz Model Analysis for Batch Export from MFP3-D AFM machine (reads text files
generated by the computer)
function elasticity = massexcompile(folderin)
mainfolder = cd
format long
fnames = dir(folderin);
numfids = length(fnames);
cd(folderin);
%filtering out irrelevent "files" such as '.' and '..'
cellnames = {};
for c = 1:numfids;
if 'C' == fnames(c).name(1) % 'C' represents the letter that the
relevent file names begin with
cellnames{end+1} = fnames(c).name;
end
end
%combine every 3 files and write
counter = 1;
numcell = length(cellnames);
numfile = 1;
elasticity = [];
% OMIT THIS WHILE LOOP IF YOU WANT TO LOAD CELLS INDIVIDUALLY
while counter <= numcell
a = load(cellnames{counter});
c = load(cellnames{counter+2});
cd(mainfolder);
elasticity(end+1,[1,2]) = elast_analysis(c,a,mainfolder);
counter = counter+3;
cd(folderin);
%numfile = numfile+1
end

function e = elast_analysis(c,a,mainfolder)
cd(mainfolder)
format long
k = 0.1416; %spring constant value N/m
v = 0.5; %poisson's ratio
R = 2.5*10^-6; % tip radius in meters
L = 10*10^-9 ;
%lower bound for elasticity (in m from contact
point)
U = 700*10^-9 ;
%upper bound for elasticity (in m from contact point)
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%adjust deflection
ak = a.*k;
%filter deflection values
d = AFM_butter(ak);
%Separation of extension and retraction
l = floor(length(c)/2);
xe = c(200:l);% add 200 in order to omit first several data points
(irratic behavior due to filtering
ye = d(200:l);
if rem(length(c),2)==0;
xr = c(end-200:-1:l+1); % subtract 200 in order to omit first
several data points
yr = d(end-200:-1:l+1);
else
xr = c(end-200:-1:l+2);
yr = d(end-200:-1:l+2);
end
%correct x,y offsets
[xe,ye] = xycorrect(xe,ye);
[xr,yr] = xycorrect(xr,yr);
format long;
erange = [];
for i = [1:1:length(xe)];
if xe(i)>=L && xe(i)<=U;
erange(end+1) = i;
end;
end;
rrange = [];
for i = [1:1:length(xr)];
if xr(i)>=L && xr(i)<=U;
rrange(end+1) = i;
end;
end;
emodulus = mean((3.*ye(erange).*(1v^2))./(4.*xe(erange).^(3/2).*R.^(1/2)));
rmodulus = mean((3.*yr(rrange).*(1v^2))./(4.*xr(rrange).^(3/2).*R.^(1/2)));
e = [emodulus, rmodulus];
function [i] = AFM_butter(x) %applies butterworth filter to data
format long
[b,a]=butter(3,.025);
i=filter(b,a,x);
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function [xc,yc] = xycorrect(x,y)
s = 0.002; %slope sensitivity

%correction for y
format long
region = [1:length(x)/4];
slope = polyfit(x(region),y(region),1);
yci = y-(slope(1).*y);
%correction for x
numslope = diff(yci)./diff(x);
index = 1;
condition = 0;
contactx = 0;
while condition == 0 && index ~= length(numslope)
if numslope(index) > s && mean(numslope(index:5:index+200)) > s;
condition = 1;
contactx = index;
end
index = index+1;
end
xc = x-x(contactx);
% correct again for y
yc = yci-yci(contactx);
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